BNP Paribas Financial Markets
CADX

BNP Paribas Financial Markets’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

BNP Paribas Financial Markets’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,048
Closed -$9.48K – 4212
2013
Q4 		$9.48K Sell
1,048
-16,186
-94% -$117K ﹤0.01% 2677
2013
Q3 		$109K Sell
17,234
-3,920
-19% -$24.9K ﹤0.01% 2404
2013
Q2 		$144K Buy
+21,154
New +$147K ﹤0.01% 2451

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

BNP Paribas Financial Markets's CADX Position: Q1 2014 in Review

BNP Paribas Financial Markets sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 1,048 shares — an estimated $9.48K sold.

BNP Paribas Financial Markets first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $144K in Q2 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • BNP Paribas Financial Markets reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 1,048 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $9.48K.
  • BNP Paribas Financial Markets first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • BNP Paribas Financial Markets's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $144K in Q2 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2014, filed 13 May 2014.